Somasundaram Subramaniam
Co-Founder & Managing Partner @ New Science Ventures
New York, United States
Somasundaram Subramaniam is a Series B investor at New Science Ventures in New York focused on Health Care and Biotechnology. Somasundaram Subramaniam is based out of New York, New York and is the Co-Founder & Managing Partner of New Science Ventures. Somasundaram previously worked at McKinsey & Company as a Director. Somasundaram Subramaniam attended the Harvard Business School.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Somasundaram Subramaniam invests in
Stages Somasundaram Subramaniam invests in
Countries Somasundaram Subramaniam invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (26%)
- Biotechnology 5 (26%)
- Manufacturing 5 (26%)
- Medical 3 (16%)
- Electronics 3 (16%)
Stage
- Series B 8 (42%)
- Series A 5 (26%)
- Funding Round 3 (16%)
- Series C 1 (5%)
- Convertible Note 1 (5%)
Country
- United States 9 (47%)
- United Kingdom 3 (16%)
- Canada 1 (5%)
- The Netherlands 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| OSCP is producing a family of micro-scale optical-integrated Gyroscopes and 6-axis Inertial Measurement Units (IMUs) that can easily deliver far better than 1°/hour performance in harsh environments reliably. However, unlike today's optical gyroscopes solutions such as FOGs (Fiber-Optic Gyro), OSCP will deliver this precision performancein a compact low-power, low-cost footprint. Compared to FOG-based IMUs, OSCP's solutions is 50x smaller, uses 8x less power, significantly cheaper, and 3x more reliable. As compared to today's low-cost, MEMS-based IMU solutions, OSCP's solutions are both dramatically higher-performance and much less sensitive to environmental effects such as Thermal Drift, Vibration induced Noise, and EMI. | Series A / Oct 01, 2026 | ||
| Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs. | $101.3M / Venture - Series Unknown / Sep 29, 2025 | ||
| Pakal Technologies is a developer of IGTO-based semiconductors intended to revolutionize the IGBT market. The company's semiconductors use IGTO, a silicon device, that is a drop-in replacement for IGBTs and provides a significant performance upgrade, providing clients with efficient, scalable, and compatible semiconductors. | $25M / Series B / Jan 29, 2025 | ||
| Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs. | $56M / Series B / Oct 05, 2023 | ||
| Paragraf is the world’s leading graphene-based electronic device design, development and manufacturing company. Building on our proprietary process to grow graphene directly on standard semiconductor industry substrates, Paragraf has pioneered the delivery of two-dimensional technologies at scale. Paragraf’s high-quality graphene – integratablewith standard semiconductor tool process lines – has unlocked the incorporation of this remarkable material into both existing and new electronic devices and applications. Through our world-first dedicated graphene device foundry, Paragraf delivers high-performance, low-power technologies to multiple markets and offers two-dimensional-material foundry services to customers and partners, providing graphene in chips to their device requirements. | $60M / Series B / Mar 01, 2022 | ||
| NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models. | $80M / Series C / Dec 17, 2021 | ||
| BrightVolt is an innovative manufacturer of solid-state thin & flexible lithium polymer batteries and power-efficient thin & flexible microelectronics for IoT clients. It specializes in the fields of battery, electronics, and manufacturing. BrightVolt got recapitalization in November 13, 2013. | $16M / Series B / Oct 06, 2021 | ||
| Phase Four is a provider of electric propulsion (EP) for small satellites.The company was founded in 2015 to accelerate the advancement of its core differentiator, the Radio Frequency Thruster (RFT). The hallmark of Phase Four’s RFT is simplicity. Because the RFT omits a hollow cathode and high voltage electronics, three key improvements arerealized: 1) a 10x materials cost savings versus legacy EP systems, 2) a significant decrease in the size of power electronics, and 3) propellant agnosticism. In a first for EP, the Phase Four RF thruster accomplishes this while achieving performance in the same thrust, specific impulse (Isp), and efficiency class as legacy plasma propulsion solutions. | $26M / Series B / Jun 11, 2021 | ||
| BrightVolt is an innovative manufacturer of solid-state thin & flexible lithium polymer batteries and power-efficient thin & flexible microelectronics for IoT clients. It specializes in the fields of battery, electronics, and manufacturing. BrightVolt got recapitalization in November 13, 2013. | $6M / Convertible Note / Jan 20, 2019 | ||
| Escalier Biosciences BV is a privately held biopharmaceutical company developing novel small molecule therapeutics that target ROR?t for the treatment of psoriasis and other autoimmune disorders. Escalier's lead topical and oral drug candidates are currently in late stage preclinical studies. Escalier is registered in The Netherlands withoffices in Nijmegen, The Netherlands and Encinitas, California. | $19M / Series B / Mar 13, 2018 | ||
| See all 19 investments → | |||
Co-Investors
About New Science Ventures
New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companies using science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.
New Science Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Somasundaram Subramaniam
Co-Founder & Managing Partner
|
|||
Andrew Abrams
Vice President
|
|||
Brenda Marex
CFO
|
|||
Jean-Pierre Bizet
Partner
|
|||
|
John Cecil
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Somasundaram Subramaniam invest in?
Somasundaram Subramaniam invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series B and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Somasundaram Subramaniam?
Public channels for Somasundaram Subramaniam include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Somasundaram Subramaniam last invest?
The most recent investment recorded for Somasundaram Subramaniam closed in Oct 2026. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
